Finally, the naturally occurring form of soluble (s)VEGFR1 (or sFLT1) is an endogenous inhibitor of the VEGF pathway, which has been also been associated with response to antiangiogenic therapies in HCC and other cancers, but also with underlying liver disease [17,18,19,20]. Here, VEGFA is linked to liver disorder.